Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Risk and Volatility
Creative Medical Technology has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.
Insider & Institutional Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $10,000.00 | 678.77 | -$5.99 million | ($2.07) | -0.50 |
| Gain Therapeutics | $50,000.00 | 1,553.58 | -$20.16 million | ($0.50) | -3.56 |
Creative Medical Technology has higher earnings, but lower revenue than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Creative Medical Technology and Gain Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
Analyst Recommendations
This is a summary of current ratings and target prices for Creative Medical Technology and Gain Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 321.35%. Given Gain Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Creative Medical Technology.
Summary
Gain Therapeutics beats Creative Medical Technology on 8 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
